The mRNA Synthesis Raw Materials Market Size is valued at USD 3.47 Billion in 2023 and is predicted to reach USD 14.91 Billion by the year 2031 at a 20.48% CAGR during the forecast period for 2024-2031.
Key Industry Insights & Findings from the Report:
- Leading pharmaceutical companies new product introductions that improve service quality, rising service standards, and increased facility personalization are driving the RNA synthesis raw material market.
- A greater understanding of the significance of early detection and treatment of chronic diseases among the general public and healthcare professionals is anticipated to fuel market growth.
- North America dominated the market and accounted for a revenue share of global revenue in 2023.
- Expanding mRNA synthesis of raw materials is hindered by a lack of flexible, durable, and cost-effective manufacturing procedures.
mRNA is a superior platform for creating preventative or therapeutic vaccines for various chronic and infectious diseases because it is adaptable and flexible. mRNA vaccines are more efficacious, have better immunogenicity, and cost less to produce than traditional treatments. For the projection period, mRNA synthesis and production services are anticipated to have rapid market expansion due to ongoing breakthroughs and advancements. Due to the key market players' goal of providing superior quality and efficacy products, there is an increasing demand for high-quality raw materials for efficient mRNA synthesis. This is essential for developing safe and effective pharmaceutical goods, vaccines, and medications. Key competitors' alliances, acquisitions, and partnerships to increase the supply of raw materials also drive the industry. The market is expanding due to new pharmaceutical companies' inventions, improved medical technology, and greater customization of facilities and services with higher quality and effectiveness.
Competitive Landscape
Some major key players in the mRNA synthesis raw materials market :
- Hoffmann-La Roche Ltd.
- Jena Bioscience GmbH
- Merck KGaA
- Yeasen Biotechnology (Shanghai) Co., Ltd.
- BOC Sciences
- Thermo Fisher Scientific, Inc.
- Maravai LifeSciences
- New England Biolabs
- Creative Biogene
- HONGENE
Market Segmentation:
The mRNA synthesis raw materials market is segmented on the try, applications and end-use. Based on the product type, the mRNA synthesis raw materials market is segmented into capping enzymes, DNA templates, nucleotides, and polymerase. The mRNA synthesis raw materials market is segmented based on applications into therapeutics production, vaccine production, and drug discovery. Based on end-use, the mRNA synthesis raw materials market is segmented into biotechnology companies, pharmaceutical companies, research and academic institutes, and others.
Based On Type, The Nucleotide Segment Is A Significant Contributor To The mRNA Synthesis Raw Materials Market.
The market's leading segment is nucleotide due to the penetration of nucleotides in applications such as nutraceuticals, pharmaceuticals, food and beverage additives, diagnostics research, and others. The market for nucleotides is experiencing explosive expansion thanks to the usage of nucleotides in boosting immunity. A strong network of raw materials vendors and suppliers is required for production to run smoothly. As a result, the participants network with suppliers of raw materials and merchandise.
The Research And Academic Institutes Segment Witnessed Growth At A Rapid Rate.
Research and academic institutes grabbed the highest revenue share, and it is anticipated that they will continue to hold that position during the expected time owing to the wide acceptance of mRNA synthesis in academia and research. The sub-rapid segment's expansion is attributable to funding from the government, support from other organizations, and collaborations between various groups from different locations. Throughout the forecast period, such variables could generate significant potential for the sub-segment.
The North American mRNA Synthesis Raw Materials Market Holds A Significant Regional Revenue Share.
The North American mRNA synthesis raw materials market is expected to register the highest market share in revenue soon. Due to the presence of significant mRNA vaccine production facilities, the United States is expected to maintain its leadership in the industry. Leading firms with well-established production facilities for mRNA vaccines and treatments, such as Pfizer and Moderna, have facilities in the United States, which will help this area continue its dominance during the projection period. In addition, Asia Pacific is projected to increase in the global mRNA synthesis raw materials market because of increased spending on research and development, a rise in the prevalence of chronic diseases, and the quick uptake of cutting-edge technologies.
Recent Developments
- In Nov 2021, BOC RNA declared the growth of its oligo synthesis services with the intention of catering to a more diverse clientele within the biomedical sector. In addition to natural DNA, siRNA, mRNA, and DNA/RNA oligos, BOC RNA offered a variety of oligonucleotides and derivative synthesis services, including non-natural and more stable oligonucleotides (cGMP grade and non-cGMP grade).
- In Sept 2022, Thermo Fisher Scientific introduced scalable mRNA production solutions utilizing customized Dynabeads. Utilizing Streptavidin for In Vitro Transcription and Carboxylic Acid for RNA Purification by Dynabeads enabled scalable, GMP-grade mRNA synthesis and purification for vaccine research and production. The Thermo ScientificTM TheraPureTM GMP portfolio of nucleotides and enzymes facilitated the workflow by providing solutions suitable for their intended use. It assisted mRNA companies in advancing more rapidly from development to commercialization.
mRNA Synthesis Raw Materials Market Report Scope
|
Report Attribute |
Specifications |
|
Market Size Value In 2023 |
USD 3.47 Billion |
|
Revenue Forecast In 2031 |
USD 14.91 Billion |
|
Growth Rate CAGR |
CAGR of 20.48 % from 2024 to 2031 |
|
Quantitative Units |
Representation of revenue in US$ Million and CAGR from 2024 to 2031 |
|
Historic Year |
2019 to 2023 |
|
Forecast Year |
2024-2031 |
|
Report Coverage |
The forecast of revenue, the position of the company, the competitive market structure, growth prospects, and trends |
|
Segments Covered |
By Type, By Application, By End-User |
|
Regional Scope |
North America; Europe; Asia Pacific; Latin America; Middle East & Africa |
|
Country Scope |
U.S.; Canada; U.K.; Germany; China; India; Japan; Brazil; Mexico ;The UK; France; Italy; Spain; China; Japan; India; South Korea; South East Asia; South Korea; South East Asia |
|
Competitive Landscape |
F. Hoffmann-La Roche Ltd., Jena Bioscience GmbH, Merck KGaA, Yeasen Biotechnology (Shanghai) Co., Ltd., BOC Sciences, Thermo Fisher Scientific, Inc., Maravai LifeSciences, New England Biolabs, Creative Biogene, HONGENE |
|
Customization Scope |
Free customization report with the procurement of the report and modifications to the regional and segment scope. Particular Geographic competitive landscape. |
|
Pricing And Available Payment Methods |
Explore pricing alternatives that are customized to your particular study requirements. |
Corporate
Office :
Office No.5170, 5th Floor Marvel Fuego, Magarpatta Rd, Pune, 411028
info@insightaceanalytic.com
